Semzuvolimab is under clinical development by United Biomedical and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Semzuvolimab’s likelihood of approval (LoA) and phase transition for Human Immunodeficiency Virus (HIV) Infections (AIDS) took place on 06 Jun 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Semzuvolimab Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Semzuvolimab overview

UB-421 is under development for the prevention of HIV-1 infections. The drug candidate is administered through intravenous and subcutaneous route. UB-421 is a monoclonal antibody (mAb) dB4C7 immunotherapy for HIV infection (AIDS). The drug candidate is developed based on using UBITh technology.

United Biomedical overview

United Biomedical (UBI) is a biopharmaceutical company that discovers, develops and commercializes vaccines and immunotherapeutics for chronic and infectious diseases. The company’s product portfolio includes peptide-based biological which is used for the treatment of Hepatitis C Virus, HIV, severe acute respiratory syndrome, alzheimer’s disease and allergy. It uses its proprietary peptide technology, vaccine formulation systems, and methods to produce a line of blood screening diagnostics and synthetic peptide vaccines in human and animal applications. UBI also provides animal health vaccines and diagnostics for foot and mouth vaccine. Its products are used in proprietary designer peptides, vaccine formulation systems and methods to manufacture therapeutic monoclonal antibodies. The company has operations in the US, China and Taiwan. UBI is headquartered in Hauppauge, New York, the US.

Quick View Semzuvolimab LOA Data

Report Segments
  • Innovator
Drug Name
  • Semzuvolimab
Administration Pathway
  • Intravenous
  • Subcutaneous
Therapeutic Areas
  • Infectious Disease
Key Developers
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.